Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib

John Nemunaitis, Sebastian Bauer, Jean Yves Blay, Khalil Choucair, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret Von Mehren, John Zalcberg, Haroun Achour, Rodrigo Ruiz-Soto, Michael C. Heinrich

Research output: Contribution to journalArticleOtherpeer-review

46 Citations (Scopus)

Abstract

Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor following imatinib. The primary end point is progression-free survival and key secondary objectives include objective response rate and overall survival. Clinical Trial Registration: NCT0367350.

Original languageEnglish
Pages (from-to)4251-4264
Number of pages14
JournalFuture Oncology
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • DCC-2618
  • gastrointestinal stromal tumor
  • KIT
  • PDGFRA
  • Phase III trial
  • receptor tyrosine kinase
  • ripretinib
  • sarcoma
  • targeted therapy
  • tyrosine kinase inhibitor

Cite this